Aller au contenu principal

 Articles scientifiques

Approaches to Fertility Preservation for Young Women With Breast Cancer.

Auteurs : Razeti MG, Soldato D, Arecco L, Levaggi A, Puglisi S, Solinas C, Agostinetto E, Spinaci S, Lapuchesky L, Genova C, Massarotti C, Lambertini M
Année : 2023
Journal : Clin Breast Cancer
Volume : 23
Pages : 241-248

Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer.

Auteurs : Chic N, Luen SJ, Nuciforo P, Salgado R, Fumagalli D, Hilbers F, Wang Y, de Azambuja E, Làng I, Di Cosimo S, Saura C, Huober J, Prat A, Loi S
Année : 2022
Journal : J Natl Cancer Inst
Volume : 114(3)
Pages : 467-70

Incorporation of TILs in daily breast cancer care: how much evidence can we bear?

Auteurs : Lænkholm AV, Callagy G, Balancin M, Bartlett JMS, Sotiriou C, Marchio C, Kok M, Dos Anjos CH, Salgado R
Année : 2022
Journal : Virchows Arch
Volume : 480
Pages : 147-162

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.

Auteurs : Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart-Gebhart M, Roblin E, Michiels S
Année : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 3

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY

Auteurs : Gelber Rd, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M
Année : 2022
Journal : Eur J Cancer
Volume : 166
Pages : 219-228

Characterization of Immunoactive and Immunotolerant CD4+ T Cells in Breast Cancer by Measuring Activity of Signaling Pathways That Determine Immune Cell Function.

Auteurs : Wesseling-Rozendaal Y, van Doorn A, Willard-Gallo K, van de Stolpe A
Année : 2022
Journal : Cancers (Basel)
Volume : 14

Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.

Auteurs : Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, Popovic L, Solinas C, Kok M, de Azambuja E, Lambertini M
Année : 2022
Journal : Expert Opin Investig Drugs
Volume : 31
Pages : 567-591

A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma.

Auteurs : Gourari K, Catherine J, Garaud S, Kerger J, Lepida A, Georgala A, Lebrun F, Gomez Galdon M, Gil T, Willard-Gallo K, Langouo Fontsa M
Année : 2022
Journal : Diagnostics (Basel)
Volume : 12

Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively.

Auteurs : Salgado R, Fineberg S, De Caluwe A, de Azambuja E
Année : 2022
Journal : Eur J Cancer
Volume : 168
Pages : 138-140

T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy.

Auteurs : Garaud S, Dieu-Nosjean MC, Willard-Gallo K
Année : 2022
Journal : Nat Commun
Volume : 13
Pages : 2259

Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.

Auteurs : Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, Vernieri C
Année : 2022
Journal : J Natl Cancer Inst
Volume : 114
Pages : 1720-1727

International consensus on radiotherapy in metastatic non-small cell lung cancer.

Auteurs : Zhu Z, Ni J, Cai X, Su S, Zhuang H, Yang Z, Chen M, Ma S, Xie C, Xu Y, Li J, Ge H, Liu A, Zhao L, Rao C, Bi N, Hui Z, Zhu G, Yuan Z, Wang J, Zhou W, Rim CH, Navarro-Martin A, Vanneste BGL, Ruysscher D, Choi JI, Jassem J, Chang JY, Kepka L, Käsmann L, Milano MT, Van Houtte P, Suwinski R, Traverso A, Doi H, Suh YG, Noël G, Tomita N, Kowalchuk RO, Sio TT, Li B, Lu B, Fu X
Année : 2022
Journal : Transl Lung Cancer Res
Volume : 11
Pages : 1763-1795

Thromboembolism and Immune Checkpoint Blockade in Cancer Patients: An Old Foe for New Research.

Auteurs : Langouo Fontsa M, Aiello MM, Migliori E, Scartozzi M, Lambertini M, Willard-Gallo K, Solinas C
Année : 2022
Journal : Target Oncol
Volume : 17
Pages : 497-505

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.

Auteurs : Martins-Branco D, Nader-Marta G, Tecic Vuger A, Debien V, Ameye L, Brandão M, Punie K, Loizidou A, Willard-Gallo K, Spilleboudt C, Awada A, Piccart M, de Azambuja E
Année : 2022
Journal : J Cancer Res Clin Oncol
Pages : 1-6

Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis.

Auteurs : Cau R, Solinas C, De Silva P, Lambertini M, Agostinetto E, Scartozzi M, Montisci R, Pontone G, Porcu M, Saba L
Année : 2022
Journal : Int J Cancer
Volume : 151
Pages : 1860-1873

PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment.

Auteurs : Thouvenin J, Van Marcke C, Decoster L, Raicevic G, Punie K, Vandenbulcke M, Salgado R, Van Valckenborgh E, Maes B, Joris S, Steichel DV, Vranken K, Jacobs S, Dedeurwaerdere F, Martens G, Devos H, Duhoux FP, Rasschaert M, Pauwels P, Geboes K, Collignon J, Tejpar S, Canon JL, Peeters M, Rutten A, Van de Mooter T, Vermeij J, Schrijvers D, Demey W, Lybaert W, Van Huysse J, Mebis J, Awada A, Claes KBM, Hebrant A, Van der Meulen J, Delafontaine B, Bempt IV, Maetens J, de Hemptinne M, Rottey S, Aftimos P, De Grève J
Année : 2022
Journal : ESMO Open
Volume : 7
Pages : 100524

Timing evolution of lobular breast cancer through phylogenetic analysis.

Auteurs : Fimereli D, Venet D, Rediti M, Boeckx B, Maetens M, Majjaj S, Rouas G, Marchio C, Bertucci F, Mariani O, Capra M, Bonizzi G, Contaldo F, Galant C, Van den Eynden G, Salgado R, Biganzoli E, Vincent-Salomon A, Pruneri G, Larsimont D, Lambrechts D, Desmedt C, Brown DN, Rothé F, Sotiriou C
Année : 2022
Journal : EBioMedicine
Volume : 82
Pages : 104169

Biomarkers and immunotherapy: where are we?

Auteurs : Langouo Fontsa M, Padonou F, Willard-Gallo K
Année : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 579-586

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial.

Auteurs : Schwarze JK, Garaud S, Jansen YJL, Awada G, Vandersleyen V, Tijtgat J, de Wind A, Kristanto P, Seremet T, Willard-Gallo K, Neyns B
Année : 2022
Journal : Cancers (Basel)
Volume : 14

Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression.

Auteurs : Pellegrino B, Hlavata Z, Migali C, De Silva P, Aiello M, Willard-Gallo K, Musolino A, Solinas C
Année : 2021
Journal : Mol Diagn Ther
Volume : 25
Pages : 409-424